Shionogi-ViiV Healthcare announces positive initial data from phase III study of dolutegravir-based regimen vs Atripla in HIV London, United Kingdom, 11 July 2012: Shionogi-ViiV Healthcare LLC today announced that initia

First Page		Document Content
Date: 2014-11-03 11:26:18 Organofluorides Medicine Fixed dose combination Bristol-Myers Squibb Cyclopropanes Emtricitabine/tenofovir/efavirenz Antiretroviral drug Abacavir Lamivudine Chemistry Pharmacology Gilead Sciences		Shionogi-ViiV Healthcare announces positive initial data from phase III study of dolutegravir-based regimen vs Atripla in HIV London, United Kingdom, 11 July 2012: Shionogi-ViiV Healthcare LLC today announced that initia Add to Reading List Source URL: shionogi616.tew-staging.com Download Document from Source Website File Size: 88,25 KB Share Document on Facebook

	DEPARTMENT OF BIOCHEMISTRY FRONTIERS PROFESSOR KENNETH JOHNSON Roger J. Williams Centennial Professor of Biochemistry, University of Texas, USA DATE DocID: 1pw8Q - View Document
	Agence nationale de recherches sur le sida et les hépatites virales : essais thérapeutiques VIH (aoûtANRS 167 LAMIDOL Essai pilote évaluant un traitement de maintenance par lamivudine et dolutégravir chez le DocID: 1nVRg - View Document
	Microsoft WordNational Summit Evaluation DocID: 1lQ90 - View Document
	Agence nationale de recherches sur le sida et les hépatites virales : essais thérapeutiques VIH (aoûtANRS 167 LAMIDOL Essai pilote évaluant un traitement de maintenance par lamivudine et dolutégravir chez le DocID: 1lhUm - View Document
	HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use FULYZAQ safely and effectively. See full prescribing information for FULYZAQ. FULYZAQ ® (crofelemer) delayed-releas DocID: 1gtlL - View Document